Improving outcomes for stem cell transplants using specialized immune cells
Official title: Developing allogeneic iNKT cell adoptive therapy to improve outcomes for HSCT indications
Funded at Mink Therapeutics INC · NIH-11185953 · Data updated 2026-11-12
This study is testing a new treatment called agenT-797 that uses special immune cells to help make stem cell transplants safer and more effective for patients, without the need for matching or extra preparation.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mink Therapeutics INC NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | May 9, 2025 |
| Project end | April 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $306,500 |
| NIH project number | 1R41AI192061-01 |
| Project ID | NIH-11185953 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include patients undergoing hematopoietic stem cell transplantation who are at risk for complications such as graft-versus-host disease.
✕Less likely to help
Patients who are not undergoing stem cell transplantation or those with contraindications to immunotherapy may not benefit from this research.
What this research studies
This research focuses on developing a new type of immunotherapy using invariant Natural Killer T (iNKT) cells to enhance the success of hematopoietic stem cell transplantation (HSCT). The therapy, known as agenT-797, is designed to be an 'off-the-shelf' product that does not require prior matching or lymphodepletion, making it more accessible for patients. The study aims to evaluate how well these iNKT cells can reduce complications like graft-versus-host disease (GvHD) and improve the integration of transplanted cells into the patient's immune system. Patients will be monitored for safety and effectiveness based on previous trials that have shown promising results.
Why it matters
Potential benefit: If successful, this research could significantly improve the outcomes of stem cell transplants, reducing complications and enhancing recovery for patients.
How similar studies have gone: Previous studies have shown promising results with similar immunotherapeutic approaches, indicating potential for success in this novel application.
Where this research is happening
-
Mink Therapeutics INC
New York, United States Active
Researchers
- Principal investigator: Le Tonqueze, Olivier — Mink Therapeutics INC
- Study coordinator: Le Tonqueze, Olivier
Related research
Other NIH-funded projects on the same topics.
-
Allogeneic iNKT cell therapy to improve HSCT outcomes
A new off-the-shelf immune cell therapy using donor iNKT cells aims to reduce complications and improve immune reconstitution after stem cell transplantation.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.